Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL931109 | 1.00 | KDM4E (0.39) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL927049 | 1.00 | KDM4E (0.39) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL2548198 | 0.95 | KDM4E (0.39) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL17688155 | 0.95 | KDM4E (0.39) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL924034 | 0.95 | KDM4E (0.39) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL7273258 | 0.95 | KDM4E (0.39) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL4829843 | 0.95 | KDM4E (0.39) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL14268316 | 0.95 | KDM4E (0.39) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL12908143 | 0.92 | KDM4E (0.33) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL14559618 | 0.90 | USP2 (0.42) | KDM4EUSP2ALDH1A1LMNAMMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | TRPV4, TRPC4, TRPV1 | KDM4E 1551/4885USP2 4586/4885ALDH1A1 1565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.